|
gptkbp:instanceOf
|
gptkb:Company
|
|
gptkbp:acquisition
|
gptkb:BioReference_Laboratories
gptkb:Eagle_Pharmaceuticals
gptkb:Prolor_Biotech
Renaissance_Health
|
|
gptkbp:CEO
|
gptkb:Phillip_Frost
|
|
gptkbp:clinicalTrials
|
ongoing
Phase 1
Phase 2
Phase 3
|
|
gptkbp:employees
|
over 1,000
|
|
gptkbp:focus
|
biomarkers
patient-centered care
value-based care
precision medicine
innovative healthcare solutions
healthcare_solutions
|
|
gptkbp:focusArea
|
rare diseases
chronic diseases
therapeutics
diagnostics
|
|
gptkbp:founded
|
2013
|
|
gptkbp:founder
|
gptkb:Phillip_Frost
|
|
gptkbp:headCoach
|
gptkb:Dr._David_O._W._H._Lee
|
|
gptkbp:headquarters
|
gptkb:Miami,_Florida
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
OPKO 1900
|
|
gptkbp:industry
|
biotechnology
|
|
gptkbp:investmentFocus
|
$100 million in acquisitions
$30 million in clinical trials
$50 million in research
|
|
gptkbp:market
|
gptkb:OPKO's_Vitamin_D_Test
gptkb:Rayaldee
gptkb:OPKO's_Molecular_Diagnostics
gptkb:OPKO's_Growth_Hormone
approximately $1 billion
4Kscore Test
|
|
gptkbp:partnerships
|
gptkb:Mayo_Clinic
gptkb:Mount_Sinai_Health_System
gptkb:Johns_Hopkins_University
gptkb:Stanford_University
gptkb:University_of_California,_San_Francisco
gptkb:Pfizer
gptkb:University_of_Miami
gptkb:Teva_Pharmaceuticals
gptkb:Cleveland_Clinic
|
|
gptkbp:products
|
diagnostic tests
therapeutics
|
|
gptkbp:researchFocus
|
diagnostic and therapeutic products
|
|
gptkbp:revenue
|
$200 million (2020)
|
|
gptkbp:stockSymbol
|
OPK
|
|
gptkbp:subsidiary
|
gptkb:OPKO_Health,_Inc.
|
|
gptkbp:tradedOn
|
gptkb:NASDAQ
|
|
gptkbp:website
|
www.opko.com
|